Tibor Kovacsovics: CX-01 Associated With High Response Rates in Older Patients With AML
Tibor Kovacsovics, MD, discusses CX-01, a heparin derivative that induced high response rates in older patients newly diagnosed with acute myeloid leukemia.
Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma
Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.
Iman Abou Dalle: Leuprolide Improves Post-Chemotherapy Recovery in Patients With Leukemia
Iman Abou Dalle, MD, describes how blocking luteinizing hormone receptors with leuprolide can improve hematopoietic recovery in patients with leukemia who have undergone intensive...
Naveen Pemmaraju: A New Option for Myelofibrosis?
Naveen Pemmaraju, MD, discusses results from a phase I/II trial of tagraxofusp in patients with relapsed/refractory myelofibrosis, a disease with only one approved treatment option.
David Sallman: Early Results of 5F9 in AML and MDS
David Sallman, MD, discusses the initial results seen in a phase Ib trial of the anti-CD47 antibody 5F9 in patients with acute myeloid leukemia...
Catherine Diefenbach: Polatuzumab Vedotin for Follicular Lymphoma
Dr. Diefenbach shares results from a phase Ib/II trial of polatuzumab vedotin plus obinutuzumab and lenalidomide for relapsed/refractory follicular lymphoma.
Pulling Back the Curtain: David Schenkein, MD
In more from our interview with David Schenkein, MD, he shares the secret to his success and the advice that he would pass on...
Pulling Back the Curtain: Lukas Wartman, MD
In more from our interview with Lukas Wartman, MD, he discusses his decision to go into medicine and his life as a doctor and...
Pulling Back the Curtain: Dan Pollyea, MD, MS
In more from our interview with Dan Pollyea, MD, MS, he shares what he learned from growing up watching his father practice medicine and the simple...
Rivaroxaban Prevents Cancer-Associated Venous Thromboembolism
Alok Khorana, MD, shares results from the CASSINI trial, which found that treatment with rivaroxaban reduced the risk of venous thromboembolism in patients receiving...
Current Issue
July 2019 Bonus Mid-Year Edition, Volume 5, Issue 9
This issue features a look at research espionage, coverage from the ASCO and EHA annual meetings, and more.
